Sinn W
Z Urol Nephrol. 1986 Feb;79(2):59-66.
Patients with bioptically ascertained glomerulonephritis of the years 1969-1981 were examined. At the time of the kidney biopsy etiology, onset of the disease and data of the findings were evaluated. Moreover, in 160 out of 300 patients after-examinations were performed. Especially also the examination of patients with erythrocyturia was carried out with the help of the phase contrast microscopy. In a second part of the examinations which we report on 2 therapy studies were performed. In the first therapy study the effectiveness of the therapy with prednisolone (n = 33), prednisolone + cytostatic drug (n = 43) as well as the indomethacin treatment (n = 52) in patients with and without nephrotic syndrome was examined. We found that an initial prednisolone dose of more than 50 mg/die for at least over 1 month is more successful than a low prednisolone dose. Indomethacin has no clinically provable therapeutic effect in the nephrotic syndrome. In normal renal function the duration of the disease has no ascertained influence on the results of the therapy. In the second therapy study the effectiveness of the CAA- (n = 27) and the CAAP-therapy, respectively, (n = 98) (cytostatic drugs, anticoagulant drugs, thrombocyte aggregation inhibitors and prednisolone) was investigated. The results of the therapy depending upon the clinical course and the morphological findings revealed that there is an indication to the CAA-CAAP-therapy in nephrotic syndromes in glomerulonephritis with and without sclerosation as well as in glomerulonephritis with relapsing exacerbations with and without sclerosations. No indication for this therapy is given in chronic courses of glomerulonephritis with slight proteinuria and in nephrotic syndromes with hypertension.
对1969年至1981年间经活检确诊为肾小球肾炎的患者进行了检查。在进行肾活检时,对疾病的病因、发病情况及检查结果数据进行了评估。此外,对300例患者中的160例进行了复查。尤其还借助相差显微镜对血尿患者进行了检查。在我们报告的检查的第二部分中,进行了两项治疗研究。在第一项治疗研究中,对使用泼尼松龙(n = 33)、泼尼松龙+细胞毒性药物(n = 43)以及吲哚美辛治疗(n = 52)的有或无肾病综合征的患者的治疗效果进行了检查。我们发现,初始泼尼松龙剂量超过50mg/日且至少持续1个月以上比低剂量泼尼松龙更有效。吲哚美辛在肾病综合征中没有临床可证实的治疗效果。在肾功能正常时,疾病持续时间对治疗结果没有确定的影响。在第二项治疗研究中,分别研究了CAA治疗(n = 27)和CAAP治疗(n = 98)(细胞毒性药物、抗凝药物、血小板聚集抑制剂和泼尼松龙)的效果。根据临床病程和形态学检查结果得出的治疗结果显示,对于有或无硬化的肾小球肾炎肾病综合征以及有或无复发加重的有或无硬化的肾小球肾炎,有指征采用CAA - CAAP治疗。对于轻度蛋白尿的慢性肾小球肾炎病程以及伴有高血压的肾病综合征,没有该治疗的指征。